Article
BMP signaling promotes the growth of primary human colon carcinomas in vivo.
Department of Genetic Medicine and Development, University of Geneva School of Medicine, 8242 CMU, 1 rue Michel Servet, CH-1211 Geneva, Switzerland.
Journal of Molecular Cell Biology
12/2010;
2(6):318-32.
DOI:10.1093/jmcb/mjq035
pp.318-32
Source: PubMed
-
Citations (0)
- Cited In (1)
-
Article: Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LH(BETA)T(AG) retinal tumors.
[show abstract] [hide abstract]
ABSTRACT: The purpose of this study was to evaluate the effect of 2-deoxy-D-glucose (2-DG) on the spatial distribution of the genetic expression of key elements involved in angiogenesis, hypoxia, cellular metabolism, and apoptosis in LH(BETA)T(AG) retinal tumors. The right eye of each LH(BETA)T(AG) transgenic mouse (n = 24) was treated with either two or six subconjunctival injections of 2-DG (500 mg/kg) or saline control at 16 weeks of age. A gene expression array analysis was performed on five different intratumoral regions (apex, center, base, anterior-lateral, and posterior-lateral) using Affymetrix GeneChip Mouse Gene 1.0 ST arrays. To test for treatment effects of each probe within each region, a two-way analysis of variance was used. Significant differences between treatment groups (ie, 0, 2, and 6 injections) were found as well as differences among the five retinal tumor regions evaluated (P < 0.01). More than 100 genes were observed to be dysregulated by ≥2-fold difference in expression between the three treatment groups, and their dysregulation varied across the five regions assayed. Several genes involved in pathways important for tumor cell growth (ie, angiogenesis, hypoxia, cellular metabolism, and apoptosis) were identified. 2-DG was found to significantly alter the gene expression in LH(BETA)T(AG) retinal tumor cells according to their location within the tumor as well as the treatment schedule. 2-DG's effects on genetic expression found here correlate with previous reported results on varied processes involved in its in vitro and in vivo activity in inhibiting tumor cell growth.Clinical Ophthalmology 01/2012; 6:817-30.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
activate BMP receptors
active endogenous BMP signaling
BMP receptor activity
BMP signaling
bone morphogenetic protein
CC cell survival
CCs
cell lines
cell-autonomous manner
dominant-negative BMP receptor Ib forms
familial human polyposis
Human colon carcinomas
modulating BMP pathway activity
primary CC samples
primary CC tumor growth
primary tumors
SMAD proteins
sporadic human CCs
therapeutic purposes
tumors